News | July 02, 2024
Merck and Orion announce option providing Merck global exclusive rights to Opevesostat
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
Subscribe To Our Newsletter & Stay Updated
